Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: Correlation with clinicobiologic features

被引:38
作者
Cuneo, A
Bigoni, R
Rigolin, GM
Roberti, MG
Milani, R
Bardi, A
Minotto, C
Agostini, P
De Angeli, C
Narducci, MG
Sabbioni, S
Russo, G
Negrini, M
Castoldi, G
机构
[1] Univ Ferrara, Dipartimento Sci Biomed & Terapie Avanzate, Sez Ematol, I-44100 Ferrara, Italy
[2] Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy
[3] IRCCS, Ist Dermopat Immacolata, Rome, Italy
关键词
D O I
10.1200/JCO.2000.18.13.2607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study the clinicobiologic significance of acquired 11q deletions involving the ataxia teleangiectasia locus (ATM+/-) in B-cell non-Hodgkin's lymphomas (NHL). Patients and Methods: Fifty-three indolent lymphomas and 82 aggressive lymphomas were studied by conventional cytogenetic analysis and by fluorescence in situ hybridization using an 11q22-23 probe recognizing ATM sequences. Pertinent clinical data were collected. Results: A hemizygous ATM deletion was seen in 44% to 88% of the interphase cells in 15 cases (11.1%); four patients had an indolent lymphoma (follicular center cell lymphoma), and 11 patients had an aggressive lymphoma (five mantle-cell lymphomas [MCLs] and six diffuse large-cell lymphomas). Dual-color hybridization studies showed ATM deletion to be possibly a secondary aberration in three patients with MCL. Ten out of 15 ATM+/- patients had a complex karyotype, 11 out of 15 had more than 90% abnormal metaphases (AA karyotype status), and +12, 13q14 deletion, and 17p13 deletion were seen in seven, four, and five cases, respectively. Patients with ATM+/- more frequently had a complex karyotype (P =.01) and the AA karyotype (P =.04) compared with patients without ATM+/-. With the exception of a poor performance status (P =.001), no correlation was found between ATM+/-, initial clinical variables, and complete remission rate; whereas a highly significant association was found with shorter survival (P <.0001). This cytogenetic lesion maintained its prognostic importance in multivariate analysis (P =.0004), along with performance status (P =.0006), serum lactate dehydrogenase level (P =.03), splenomegaly (P =.01), and histologic grade (P =.03). When analyzing indolent lymphomas and aggressive lymphomas separately, ATM+/- maintained its prognostic importance as an independent variable in both histologic groups (P =.0001 and P =.016, respectively). Conclusion: Though possibly not representing a primary genetic lesion in the majority of cases, the acquired ATM+/- status has clinicobiologic importance in NHL, possibly representing a major cytogenetic determinant of outcome. J Clin Oncol 18:2607-2614. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:2607 / 2614
页数:8
相关论文
共 32 条
  • [1] CABANILLAS F, 1989, AM J MED, V87, P167
  • [2] Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization
    Clodi, K
    Younes, A
    Goodacre, A
    Roberts, M
    Palmer, J
    Younes, M
    Cabanillas, F
    Andreeff, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) : 913 - 921
  • [3] CROCE CM, 1993, SEMIN ONCOL, V20, P31
  • [4] Cuneo A, 1999, HAEMATOLOGICA, V84, P589
  • [5] Cytogenetic profile of lymphoma of follicle mantle lineage:: Correlation with clinicobiologic features
    Cuneo, A
    Bigoni, R
    Rigolin, GM
    Roberti, MG
    Bardi, A
    Piva, N
    Milani, R
    Bullrich, F
    Veronese, ML
    Croce, C
    Birg, F
    Döhner, H
    Hagemeijer, A
    Castoldi, G
    [J]. BLOOD, 1999, 93 (04) : 1372 - 1380
  • [6] Cuneo A, 1997, CANCER RES, V57, P1144
  • [7] 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis
    Dohner, H
    Stilgenbauer, S
    James, MR
    Benner, A
    Weilguni, T
    Bentz, M
    Fischer, K
    Hunstein, W
    Lichter, P
    [J]. BLOOD, 1997, 89 (07) : 2516 - 2522
  • [8] Dreyling MH, 1997, CANCER RES, V57, P4608
  • [9] Fegan C, 1995, LEUKEMIA, V9, P2003
  • [10] HARRIS NL, 1994, BLOOD, V84, P1361